Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Two Presentations of Tralokinumab in Healthy Subjects
NCT04674826Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tralokinumab in atopic dermatitis (AD) (2 arms), sponsored by LEO Pharma. Primary endpoints: Area under the serum concentration time curve from time 0 extrapolated to infinity, Area under the serum concentration time curve from time 0 to time of last quantifiable concentration and 1 more. Started Feb 2021; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04674826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674826.